Overview

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis
Phase:
PHASE3
Details
Lead Sponsor:
Genexine, Inc.
Collaborator:
PT Kalbe Genexine Biologics
Treatments:
Darbepoetin alfa